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Abstract: A total of 472 epilepsy patients with a 4-year remission period were divided into 10-year
age groups according to age of onset. The relapse patterns during at least 3 years of follow-up were
classified as early relapse (ER), late relapse (LR), and seizure-free (SF). The remission probability
and multiplicity of prognostic factors were evaluated using univariate and multivariate multinomial
logistic analyses. The weighted risk score based on odd ratios (ORs) was used for comparisons of the
relative risk of relapse between groups. The group with onset in their 20s had the lowest remission
probability among the groups. The risks of relapse in the LR patients and the relative weighted risk
score of ER patients in the group with onset in their 20s were 3.11 and 19.44, respectively, which was the
highest risk among the age groups. Patients without remission within 1 year had the highest relapse
risk, with an OR of 7.18 in ER patients. The OR of relapse in patients with >10 generalized tonic–clonic
(GTC) seizures was the second most important prognostic factor in LR patients. The distinct risk and
corresponding prognostic factors in LR and ER patients reflected inherent differences between these
relapse patterns.
Keywords: epilepsy; age at onset of epilepsy; remission within 1 year; relapse pattern;
prognostic factor
1. Introduction
Age at onset of epilepsy and symptom duration have been consistently reported as important
prognostic factors. The onset age of this disease varies due to its multifaceted etiology and inevitably
affects symptom duration. Thus, the age at onset of epilepsy and symptom duration are closely
correlated with each other. It has long been known that the response to treatment in newly diagnosed
epilepsy patients is better than that in chronic epilepsy patients [1]. Thus, early effective treatment
may be important for preventing progression to chronic epilepsy. Localization-related seizures,
relevant lesions on a brain scan, achievement of seizure control within 1 year, and the total number of
generalized tonic–clonic (GTC) or generalized seizures have been reported as important prognostic
factors, in addition to conventional prognostic factors such as antecedents of epilepsy. High initial
seizure frequency before the initiation of antiepileptic drugs (AEDs) and being a non-responder without
achievement of seizure control within one year have also been reported as factors predictive of a poor
prognosis [2–6]. In contrast, some reports [7–9] have shown that early intervention with AED therapy
did not alter the long-term prognosis, leading to debate on this topic. Incomplete achievement of
remission or relapse back to the pretreatment condition result in the prolongation of the total symptom
duration. These results suggested the importance of achieving early control of seizures. Therefore,
almost all prognostic factors are related to symptom duration.
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Although age at onset of epilepsy and symptom duration have been consistently reported as
important prognostic factors, studies assessing these factors in detail according to onset age have not
yet been performed. We aimed to elucidate the prognostic implications of the age of onset stratified by
10-year increments with regard to relapse patterns among patients with 4 seizure-free years.
2. Materials and Methods
2.1. Patient Registration and Inclusion Criteria
A previous study [10] on relapse after achieving and maintaining complete seizure control for at
least four years was continued after the endpoint of the study in July 2014. A total of 525 epilepsy patients
were consecutively recruited from March 1999 to June 2017 to complete three more years of follow-up.
Thirty-three patients were lost to follow-up after the initiation of AED withdrawal, and another
20 patients were excluded for various reasons before the initiation of AED withdrawal. Patients who
had undergone epilepsy surgery, patients with juvenile myoclonic epilepsy (JME)—who exhibit a
greater tendency towards relapse—and patients with benign childhood epilepsy with centrotemporal
spikes were excluded. The presence of epileptiform discharges during the electroencephalography
examination immediately before the initiation of AED withdrawal was another exclusion criterion.
Three patients who exhibited a complex partial seizure as pure ictal amnesia only, as ascertained during
a period of remission or later, were excluded. Finally, 472 patients were enrolled (Figure 1). All of the
patients were regularly treated and followed by the corresponding author.
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year increments as follows: under 10 years of age, 20–29 years, 30–39 years, 40–49 years, and 50 years 
or older. Each of the age groups was further stratified based on the relapse patterns that were 
investigated in the previous study [10], namely, early relapse (ER), late relapse (LR), and seizure-free 
(SF). SF patients were followed for at least 3 years. 
Fig re 1. Flo c art of t e recr it e t rocess for t e i cl sio of atie ts. total of 525 e ile sy
patients ere initially recruited, and 53 patients ere excluded due to the above docu ented causes.
Finally, 472 patients ere grouped into 10-year age groups according to the age of onset and classified
as seizure-free (SF), late relapse (LR), and early relapse (ER) patients.
2.2. Patient Grouping and Follow-Up
The enrolled patients were divided into 5 groups according to seizure onset age stratified by
10-year increments as follows: under 10 years of age, 20–29 years, 30–39 years, 40–49 years, and 50 years
or older. Each of the age groups was further stratified based on the relapse patterns that were
investigated in the previous study [10], namely, early relapse (ER), late relapse (LR), and seizure-free
(SF). SF patients were followed for at least 3 years.
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2.3. AED Treatment and Policy Regarding AED Withdrawal
In principle, alternative monotherapy was attempted for the patients who had not achieved seizure
freedom with the initial monotherapy. However, considering the patient’s clinical status, an add-on
combination trial was attempted to shorten the time to achieve seizure control. Therapeutic drug
monitoring of AEDs was regularly performed to guide adjustment of the dose and monitor compliance.
Phenytoin, carbamazepine, valproate, lamotrigine, topiramate, and levetiracetam were used. In a
few patients who had been referred, phenobarbital was administered. Planned AED withdrawal was
performed as described in a previous study [10]. In the case of patients taking levetiracetam, the usual
prescribed dose was 750 to 2500 mg daily, which was gradually reduced by 250–500 mg at every visit.
2.4. Standard Protocol Approvals and Patient Consent
The study design (Institution Review Board (IRB) No. 2020-1333-001) was approved by and
adhered to the guidelines established by our hospital’s Human Research Protection Center. The need
for informed consent was waived because of the retrospective nature of this study.
2.5. Data Analysis
The demographic data included sex, mean age of epilepsy onset, and mean symptom duration
(duration > 120 months). The prognostic variables were an antecedent of epilepsy, no remission
within one year after the initiation of AED treatment, >10 generalized seizures or 2 GTC seizures
before the achievement of remission, general characteristics of the seizures such as epilepsy type
(localization-related, idiopathic generalized, or undifferentiated epilepsy), relevant lesions on brain
magnetic resonance imaging (MRI) scans, and nocturnal preponderance. The demographic data are
also presented according to the relapse pattern within each age group (Tables 1 and 2). Total symptom
duration was defined as the sum of the duration from seizure onset to registration at the epilepsy clinic
and the duration from registration to the most recent seizure attack. The total duration of the SF period
was divided into the duration from the most recent seizure attack to the initiation of AED withdrawal
and the duration of the AED withdrawal process (Table S1).
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Table 1. Demographic data and prognostic variables according to relapse pattern in groups stratified by age of onset.
Age of Onset Group,
n, (%) † Under 10 Years Old, n = 43 (9.1) 10–19 Years Old, n = 192 (40.7) 20–29 Years Old, n = 85 (18.0)
Relapse Pattern SF LR ER SF LR ER SF LR ER
n, (%) †† 14 (32.6) 12 (27.9) 17 (39.5) 62 (32.3) 77 (40.1) 53 (27.6) 22 (25.9) 39 (45.9) 24 (28.2)
Demographic data
M: F 9:5 7:5 10:7 35:27 40:37 31:22 15:7 28:11 17:7
Mean age at seizure
onset a ± SD, y 5.0 ± 2.6 5.0 ± 2.7 5.1 ± 3.1 14.1 ± 2.4 14.5 ± 2.6 13.8 ± 2.2 23.8 ± 2.9 23.9 ± 2.9 23.7 ± 2.9
Mean duration of
symptoms b ± SD, m 164.8 ± 141.8 286.7 ± 90.7 252.9 ± 108.0 138.9 ± 117.7 145.9 ± 114.2 183.3 ± 104.3 100.2 ± 95.8 95.6 ± 80.8 179.7 ± 106.6
Prognostic variables, (%) †††
Antecedents of epilepsy 7 (50.0) 7 (58.3) 10 (58.8) 20 (32.3) 28 (36.4) 23 (43.4) 9 (40.9) 14 (35.9) 12 (50.0)
Symptom duration
> 120 m 8 (57.1) 12 (100.0) 15 (88.2) 30 (48.4) 41 (53.2) 36 (67.9) 9 (40.9) 14 (35.9) 18 (75.0)
No remission within 1 y 8 (57.1) 10 (83.3) 16 (94.1) 32 (51.6) 40 (51.9) 52 (98.1) 9 (39.9) 13 (33.3) 20 (83.3)
More than 10 GTC
seizures 7 (50.0) 11 (91.7) 15 (88.2) 20 (32.3) 37 (48.1) 32 (60.4) 1 (4.5) 10 (25.6) 16 (86.7)
Localization-related
epilepsy 9 (64.3) 9 (75.0) 13 (76.5) 39 (62.9) 60 (77.9) 48 (90.6) 14 (63.6) 31 (79.5) 19 (79.2)
Relevant lesions on
brain MRI scan 4 (28.6) 4 (25.0) 11 (64.7) 11 (17.7) 22 (28.6) 18 (34.0) 10 (45.5) 13 (33.3) 14 (58.3)
Nocturnal
preponderance 3 (21.4) 6 (50.0) 5 (29.4) 21 (33.9) 24 (31.2) 13 (24.5) 10 (45.5) 14 (35.9) 8 (33.3)
SF—seizure-free; LR- late relapse; ER—early relapse; M—male; F—female; y—year; m—month; GTC—generalized tonic–clonic. a: Significant increase in the mean age at onset of epilepsy
with increasing age (p < 0.001) and no statistically significant differences among relapse patterns within each age group. b: Significant decrease in the mean symptom duration (p < 0.001).
†: The proportion of patients in each age of onset group. ††: The proportion of patients with each relapse pattern in each age of onset group. †††: The proportion of patients with prognostic
variables according to relapse pattern.
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Table 2. Demographic data and prognostic variables according to relapse pattern in groups stratified by age of onset.
Age of Onset Group,
n, (%) † 30–39 Years Old, n = 53 40–49 Years Old, n = 55 50 Years Old or Older, n = 44
Relapse Pattern SF LR ER SF LR ER SF LR ER
n (%) †† 19 (35.8) 21 (39.6) 13 (24.5) 30 (54.5) 19 (34.5) 6 (10.9) 26 (59.3) 14 (33.3) 4 (7.4)
Demographic data
M: F 11:8 13:8 6:7 19:11 5:14 4:6 15:11 6:8 3:1
Mean age at epilepsy
onset a ± SD, y. 34.6 ± 2.8 34.8 ± 3.3 34.1 ± 2.5 44.7 ± 3.5 45.3 ± 2.7 42.5 ± 2.2 58.1 ± 6.3 57.8 ± 7.1 56.8 ± 6.9
Mean duration of
symptoms b ± SD, m. 58.7 ± 72.9 66.6 ± 74.6 124.1 ± 128.4 43.6 ± 52.4 61.7 ± 61.3 61.3 ± 57.4 24.3 ± 27.6 56.2 ± 64.1 39.0 ± 34.6
Prognostic variables (%) †††
Antecedents of epilepsy 6 (31.6) 9 (42.9) 5 (38.5) 13 (43.3) 6 (31.6) 4 (66.7) 14 (53.8) 6 (42.9) 1 (25.0)
Symptom duration
> 120 m 3 (15.8) 5 (23.8) 5 (38.5) 1 (3.3) 4 (21.1) 2 (33.3) 0 (0) 2 (14.3) 0 (0)
No remission within 1 y 7 (26.8) 8 (38.1) 8(61.5) 13 (43.3) 4 (21.1) 4 (66.7) 5(19.3) 3 (11.4) 3 (75.0)
More than 10 GTC
seizures 4 (21.1) 3 (14.3) 1 (7.7) 4 (13.3) 4 (21.1) 1 (16.7) 3 (11.5) 3 (21.4) 0 (0)
Localization-related
epilepsy 12 (63.2) 17 (81.0) 12 (92.3) 25 (83.3) 16 (84.2) 6 (100) 23 (88.5) 12 (85.7) 1 (25.0)
Relevant lesions on
brain MRI scan 9 (47.4) 9 (42.9) 7 (53.8) 17 (56.7) 8 (42.1) 3 (50.0) 12 (46.2) 6 (42.9) 3 (75.0)
Nocturnal
preponderance 7 (36.8) 5 (23.8) 3 (23.1) 1 (3.3) 8 (42.1) 0 (0.0) 3 (11.5) 3 (21.4) 1 (25.0)
SF—seizure-free; LR- late relapse; ER—early relapse; M—male; F—female; y—year; m—month; GTC—generalized tonic–clonic. a: Significant increase in the mean age at onset of epilepsy
with increasing age (p < 0.001) and no statistically significant differences among relapse patterns within each age group. b: Significant decrease in the mean symptom duration (p < 0.001).
†: The proportion of patients in each age of onset group. ††: The proportion of patients with each relapse pattern in each age of onset group. †††: The proportion of patients with prognostic
variables according to relapse pattern.
Diagnostics 2020, 10, 1089 6 of 15
Perinatal insults, febrile convulsions, a family history of epilepsy, head trauma combined with
loss of consciousness for >1 h, and a history of infections of the central nervous system were regarded
as antecedents related to epilepsy. The presence of at least one of these antecedents was regarded as the
presence of antecedents. Nocturnal preponderance was defined as the occurrence of >90% of habitual
seizures during sleep. Localization-related epilepsy, including remote symptomatic epilepsy, was based
on the partial feature of ictal semiology, localized epileptiform discharge in the regular follow-up of
the electroencephalogram, which was performed at intervals of at least two years, and relevant lesions
in a brain MRI scan, defined according to the criteria for epilepsy and epileptic syndrome proposed
by the International League Against Epilepsy (ILAE) [11]. Cryptogenic epilepsy was included in
localization-related epilepsy and undifferentiated patients were treated as missing values statistically.
The mean OR of each prognostic factor in each onset age group was defined as the weighted risk
score for the evaluation of the important prognostic factors across onset age groups. However, the
relative weighted risk score based on the risk factors in SF patients as a reference was obtained as
follows: the mean ORs for each variable in LR and ER patients were divided by the mean OR of the
corresponding variable in SF patients in each age group, and the sums in each age group, obtained
from the above calculation, were divided by five, which was the total number of prognostic factors.
The mean of the multiplicity of the prognostic factors in each age group was used to evaluate the
tendency and the proportion of factors predictive of a poor prognosis in each age group.
2.6. Statistical Analysis
Kaplan–Meier curves for each onset age group were compared via the log-rank test and Bonferroni
adjustment. Important prognostic factors and the scores involving the multiplicity of the prognostic
factors in each onset age group with regard to the relapse patterns were assessed. Multicollinearity
among the variables was determined before the logistic regression analysis was performed. A univariate
multinomial logistic regression model was constructed, and the baseline level for each variable was
based on a favorable prognosis. The risk factors with a p-value <0.01 in the univariate model were
included in the multivariate multinomial logistic regression model. Multivariate multinomial logistic
regression was performed for LR and ER patients separately, with SF patients used as a reference.
ORs with 95% confidence intervals (CIs) were calculated.
3. Results
3.1. Demographic Characteristics
A total of 472 patients were enrolled, with 9.1% (43 patients), 40.7% (192 patients), 18% (85 patients),
11.2% (53 patients), 11.6% (55 patients), and 9.3% (44 patients) assigned to the following groups,
respectively: under 10 years old, 20–29 years old, 30–39 years old, 40–49 years old, and 50 years old
or older (Tables 1 and 2). The mean ages at seizure onset in these groups were 5.2 ± 2.8, 14.2 ± 2.4,
23.8 ± 2.8, 34.6 ± 2.9, 44.7 ± 3.2, and 57.9 ± 6.4 years, respectively, which were all significantly different
(p < 0.0001) (more details are presented stratified by a relapse pattern in Tables 1 and 2). There were no
statistically significant differences in the mean age at seizure onset according to the relapse pattern
within each age group. The mean duration of symptoms in all patients was 123.72 ± 113.16 months,
and that in each onset age group was 233.3 ± 124.1, 154.0 ± 113.6, 120.6 ± 97.0, 77.8 ± 92.2, 51.9 ± 55.8,
and 35.6 ± 44.6 months, respectively, which were significantly different (p < 0.0001). A significant
difference in mean symptom duration stratified by relapse patterns was also noted between the
groups that were 10–19 and 20–29 years old. There was a significant relationship between age at
onset of epilepsy and symptom duration in all subjects (correlation = 0.47, p-value < 0.001; ß = −0.06,
p-value < 0.001) (Figure 2).
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Figure 2. A relationship between age at onset of epilepsy and symptom duration. A statistically
significant relationship was noted between age at onset of epilepsy and symptom duration in all subjects.
In all patients, the mean duration of the SF period was 73.19 ± 24.12 months, the mean duration
from the most recent seizure attack to the initiation of AED withdrawal was 59.91 ± 21.33 months, and
the mean duration of the AED withdrawal process was 15.45 ± 9.19 months. There were no significant
differences between the onset age groups or between the subgroups stratified by relapse patterns
(Tables S1 and S2).
3.2. Statistical Data
The overall relapse rate was 63.5% (299 of 472 patients), and the proportions of patients with
relapse among LR and ER patients were 38.5% and 24.8%, respectively. The group with onset in their
20s had the worst remission probability according to the Kaplan–Meier curve, and the groups with
onset after age 40 had a significantly better prognosis than those with onset before age 30 according to
the log-rank test with Bonferroni adjustment (Figure 3).
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Figure 3. Re ission probabilities presented by the Kaplan– eier curve for each age group. The group
ith onset in their 20s had the orst re ission probability according to the Kaplan– eier curve, and
the groups with onset after age 40 had a significantly better prognosis than those with onset before age
30 (* significant according to the log-rank test with Bonferroni adjustment).
The variance inflation factors from the multicollinearity tests among the variables showed no
correlations (<0.8) (Table 2). Among LR patients, a symptom duration >120 months (OR: 1.76, 95%
CI: 1.13–2.70) and >10 GTC seizures (OR: 2.05, 95% CI: 1.29–3.67 and 4.30, 2.58–7.15) were found to
be significant covariates in the univariate analysis. The significant covariates in ER patients were a
symptom duration >120 months (OR: 4.31, 95% CI: 2.62–7.11), no remission within 1 year (OR: 9.98,
95% CI: 5.29–18.83), >10 GTC seizures (OR: 4.30, 95% CI: 2.58–7.15), and localization-related epilepsy
(OR: 2.68, 95% CI: 1.26–5.70). The presence of relevant lesions on brain MRI scans was not a significant
covariate but was included in the multivariable regression analysis (Table 3).
Diagnostics 2020, 10, 1089 9 of 15
Table 3. Prognostic analysis with a univariable multinomial model in relapsed patients with SF patients as the reference.
Variable Level VIF
SF Patients (Ref.)
LR Patients ER Patients
OR 95% CI p-Value OR 95% CI p-Value a
Age of onset group
Under 10 years old 2.17 1.59 0.58–4.36 0.366 7.89 2.22–28.05 0.001
10–19 years old 3.70 2.31 1.11–4.79 0.025 5.56 1.82–16.93 0.003
20–29 years old 2.58 3.29 1.43–7.58 0.005 7.09 2.13–23.56 0.001
30–39 years old 1.99 2.05 0.84–5.04 0.117 4.45 1.25–15.79 0.021
40–49 years old 2.00 1.18 0.49–2.80 0.714 1.30 0.33–5.11 0.708
50 years old or older Ref.
Antecedents of epilepsy Yes 1.72 0.94 0.62–1.44 0.780 1.34 0.83–2.15 0.229
No Ref.
Symptom duration: 120 months >120 1.18 1.76 1.13–2.70 0.013 4.31 2.62–7.11 <0.0001
≤120 Ref. Ref.
No remission within 1 year Yes 1.18 1.02 0.67–1.55 0.9371 9.977 5.288–18.826 <0.0001
No Ref. Ref.
More than 10 GTC seizures
Yes 1.37 2.05 1.29–3.67 0.003 4.30 2.58–7.15 <0.0001
No
Localization-related epilepsy Yes 1.44 1.31 0.75–2.27 0.340 2.68 1.26–5.70 0.011
No Ref. Ref.
Relevant lesions on brain MRI scan
Yes 1.12 0.9 0.58–1.39 0.643 1.60 0.99–2.58 0.053
No
VIF—variance inflation factor; SF—seizure-free; LR—late relapse; ER—early relapse; OR—odds ratio; CI—confidence interval (between lower 25% and upper 75%); Ref.—reference;
GTC—generalized tonic–clonic. a: p-value: univariate multinomial regression analysis.
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Regarding the weighted risk score, no remission within 1 year was the most important prognostic
factor in every age group in ER patients, while in SF and LR patients, localization-related epilepsy was
the most significant factor in every age group, except for the group with onset before age 10 (Figure 4).
The weighted risk score for almost all prognostic factors in every age group was higher in ER
patients than in SF and LR patients (Figure 4). The number of patients with any combination of
prognostic factors was highest in the group with onset between 10 and 19 years old, regardless of
relapse pattern (details not provided). Patients with three prognostic factors accounted for the largest
proportion, namely, 7 (53.8%) of 13 patients in the group with onset under 10 years old had a symptom
duration >120 months, no remission within 1 year, and >10 GTC seizures. In the group with onset
from 10–19 years old, the combination of a symptom duration >120 months, >10 GTC seizures, and
localization-related epilepsy accounted for the largest proportion of patients, namely, 10 (27.0%) of
37 patients. In patients whose onset ages were 20–29 years old, 30–39 years old, and 40–49 years old,
localization-related epilepsy and relevant lesions on brain MRI scans were identified in 19 (55.9%) of
34, 20 (76.9%) of 29, and 15 (75%) of 20 patients, respectively. However, in those 50 years old and older,
localization-related epilepsy was the most important prognostic factor and was present in 13 (52%)
of 25 patients (Figure 5a) (percentages not shown). A two-way ANOVA of the mean multiplicity of
prognostic factors in each age group across relapse patterns indicated a marginal significance (p = 0.08)
with a decreasing tendency, and the results in the LR and ER patients showed significant decreasing
tendencies (Figure 5b). In the multivariate multinomial logistic regression analysis with SF patients as
the reference (Table 4), the risk of relapse in LR patients was 3.11-fold higher in the group with onset in
their 20s than in any other group. There were no significant differences among any of ER patient onset
age groups. However, all the relative weighted risk scores for ER patients were higher than those for
LR patients. The score for ER group with onset in their 20s was the highest, at 19.44, while that of the
LR group with onset in their 20s was 3.22. The risk of relapse for LR patients with >10 GTC seizures
was 1.88-fold higher than that for patients without this risk factor, and the remaining covariates in LR
patients were not significant. In ER patients, the risk of relapse in patients without remission within
1 year was 7.18-fold higher (the highest risk) than that in patients without this risk factor. The risk of
relapse in patients with >10 GTC seizures, localization-related epilepsy, and relevant lesions on brain
MRI scans was 2.82-, 2.64-, and 1.83-fold higher in ER patients than in SF patients as a reference after
statistical correction for the other covariates.
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Figure 4. Important prognostic factors in each age group related to the relapse patterns. No remission
within 1 year in ER patients was the most important factor in every age group, and localization-related
epilepsy in SF and LR patients was the most important factor in every age group, except the group
with onset before age 10. The weighted risk scores for almost all prognostic factors in every age group
were higher in ER patients than in SF and LR patients.
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Figure 5. Comparison of the multiplicity (a) and mean multiplicity (b) of prognostic factors across the
age groups stratified by relapse pattern. (a) The largest proportion of patients in the group with onset
age under 10 years old had three prognostic factors *, namely, a symptom duration >120 months, no
remission within 1 year, and >10 GTC seizures. In the group with age of onset between 10 and 19 years
old, the factors were a symptom duration >120 months, >10 GTC seizures, and localization-related
epilepsy. In groups with onset at 20–29 years old, 30–39 years old, and 40–49 years old, two prognostic
factors were present in the greatest proportion of patients, namely, localization-related epilepsy
and relevant lesions on brain MRI scans. However, in the group with onset at age 50 or older,
localization-related epilepsy was the most important prognostic factor. (b) The mean multiplicities of
the prognostic factors showed marginal significance with a decreasing tendency with increasing age.
Those in LR and ER patients but not in SF patients showed a significant decreasing tendency.
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Table 4. Prognostic multivariable multinomial analysis in relapsed patients with SF patients as the reference.
Covariate Level
SF Patients (Ref.)
LR Patients ER Patients
OR (95%, CI) p-Value Relative Risk a OR (95%, CI) p-Value Relative Risk a
Age of onset group
Under 10 years old 1.17 (0.38–3.63) 0.782 2.18 1.53 (0.34–6.78) 0.580 7.58
10–19 years old 1.91 (0.86–4.25) 0.112 1.79 1.92 (0.55–6.73) 0.310 7.91
20–29 years old 3.11 (1.30–7.4) 0.011 3.22 3.42 (0.90–12.94) 0.070 19.44
30–39 years old 2.12 (0.85–5.32) 0.108 1.44 3.12 (0.79–12.35) 0.106 6.73
40–49 years old 1.17 (0.48–2.83) 0.732 3.37 0.83 (0.19–3.59) 0.804 12.99
50 years old or
older Ref. 1.41 Ref. 8.50




No remission within 1 year Yes 0.80 (0.50–1.28) 0.347
7.18 (3.63–14.22)
<0.001No Ref. Ref.





Localization-related epilepsy Yes 1.60 (0.89–2.87) 0.119
2.64 (1.14–6.13)
0.023No Ref. Ref.





SF—seizure-free; Ref.—reference; LR—late relapse; ER—early relapse; OR—odds ratio; CI—confidence interval; GTC—generalized tonic–clonic. a: Relative weighted risk score obtained
by the mean odds ratio of each prognostic factor in each onset age group.
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4. Discussion
Symptom duration is a well-known prognostic factor that is inevitably related to the age at onset
of epilepsy. In addition to the conventional prognostic factors, such as relevant lesions on brain MRI
scans and seizure classification, other prognostic factors, such as achievement of seizure control and
the total number of generalized or GTC seizures, could be related to the symptom duration. Similar to
the intercorrelation between age at onset of epilepsy and symptom duration, seizure control within the
first year after the initiation of AED treatment and the total number of generalized or GTC seizures
until the achievement of remission have been found to be temporally correlated with each other in the
early phase of epilepsy, possibly influencing symptom duration and prognosis. Many studies have
regarded the achievement of 12-month seizure control or freedom from seizures as a standard indicator
of a therapeutic response, which can be used for the prediction of prognosis after the second AED
trial [12]. The frequency and total number of seizures before or during AED treatment were identified
as significant risk factors for seizure relapse [5,13] and were also important for the early control of
seizures as clinical predictors of resistance to drug therapy [2]. The occurrence of many seizures before
therapy and an insufficient response to initial AED treatment are indicators of refractory epilepsy.
Similarly, the response to the first AED was the strongest predictor of long-term prognosis in adults
and children [13–18]. In patients with childhood temporal lobe epilepsy (TLE), failure of the first AED
trial accurately predicted refractory TLE at 2 years after the onset of seizures [15].
The overall relapse rate in this longitudinal study and the proportion of patients with relapse in
the LR and ER groups were not substantially different from those reported in a previous study [10].
These results are in accordance with previous findings [19], indicating that overall outcomes in patients
with newly diagnosed epilepsy have not markedly improved, even though many new AEDs with
different mechanisms of action have been introduced. These findings may reflect the inherent nature
of this disease entity. In terms of exclusion criteria of the recruitment process, JME, which has been
presumed to be a lifelong genetic trait with a well-known tendency to relapse after withdrawal of
AEDs. So, the majority of patients with JME need prolonged AED treatment after a follow-up of two
decades and should be processed separately for the prognostic study. In this study, one patient was
recognized before AED withdrawal and excluded, which had not an effect on the relapse rate.
A longer symptom duration does not necessarily indicate a worse prognosis. Age at onset of
epilepsy and symptom duration were found to be significantly inversely related in this study, meaning
that the symptom duration in patients with a younger age of onset was longer than that in patients
with an older age of onset. However, the significance seemed to be limited, as the results from the
multicollinearity test performed to rule out the possibility of intercorrelation among the variables
indicated that there were negative relationships between symptom duration and the other variables,
including onset age. The remission probability was the highest in the group with onset after age 50,
which was used as a reference for the multinomial regression model. The multiplicity in the prognostic
factors in each age group and the mean multiplicity of prognostic factors showed a decreasing tendency
with increasing age, regardless of relapse pattern. In addition, the multivariate multinomial logistic
regression analysis with SF patients as a reference and statistical correction for the other covariates
demonstrated that a symptom duration >120 months was not a significant prognostic factor. However,
this study was performed with patients who had been SF for four years, which was different from
previous reports [2,5,12,13]. Thus, it was difficult to directly compare the results of previous reports
with those of the present study. The dichotomized approach with the threshold of 120 months was
chosen subjectively due to the large number of patients with a symptom duration of more than 10 years,
according to the author’s experience in clinical practice. Considering that the proportion of referred
patients in this study was 58.7% (details not provided) and inadequate control of seizures was a major
reason for the transfer of care, the symptom durations were prolonged, which supported the adoption
of a 120-month threshold.
According to the results of the multivariate analysis, among LR patients, the relapse risk was
highest in the group with onset in their 20s, and the weighted relative risk score was higher in ER
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patients than in LR patients in every age group. Moreover, the score was highest in ER patients with
onset in their 20s, even higher than that of the LR patients with onset in their 30s, which indicated
that the overall prognosis was worse for ER patients than LR patients. Higher weighted risk scores
and a higher mean multiplicity of prognostic factors were identified in ER patients than in SF and
LR patients. These findings showed there were differences based on the relapse pattern. The second
most important prognostic factor in LR patients was >10 GTC seizures. Regarding the number of
seizures, the patients who reported more than 10 seizures prior to the initiation of therapy had more
than double the odds of developing refractory epilepsy [12], and a comparative study with 10 years
of follow-up [13] showed a 4.6-fold higher risk of refractory epilepsy in patients with a high initial
seizure frequency, supporting the results of this study. Several studies have suggested that there is a
relationship between a high initial seizure frequency and poor outcomes [13,20–22].
It took approximately one year of empirical treatment to determine whether AED treatment
would result in seizure control, especially among non-referred patients, which was supported by the
report [18] that 74% of patients responded to treatment within 1 year. Failure to achieve remission
within 1 year in ER patients was revealed to be a significant factor predictive of a poor prognosis
in this study. The proportion of SF patients who achieved seizure control within one year after the
initiation of AED treatment was 59%. The proportions among LR and ER patients were 55.5% and
10.3%, respectively (details not presented), but these patients ultimately experienced relapse after one
SF year.
The finding that seizure onset between the ages of 20 and 29 was an independent factor predictive
of a poor prognosis is meaningful, and the failure to achieve remission within one year and >10 GTC
seizures prior to the initiation of therapy were also found to be significant factors predictive of a poor
prognosis in this study. In addition, there were clear differences in the risk of relapse between LR and
ER patients. These results in a large study population suggest the potential efficacy of a treatment
strategy based on prognostic groups and provide further knowledge of the natural history of epilepsy.
This study design might offer a method to overcome the difficulties associated with conducting a
double-blind randomized trial. We think that this study design is not a perfect solution but is an
alternative approach for studying these issues, especially for the relapse patterns. This study was
performed in only one tertiary referral center might limit interpretation of the meaning of the result,
even the total enrolled patients were the most up to now. Additional studies are needed to confirm
these results.
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